Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma

Histopathology

Volumn 63, Issue 2, 2013, Pages 157-166

  Lehnen, Nils C ^a   von Mässenhausen, Anne ^a   Kalthoff, Holger ^b   Zhou, Hui ^a   Glowka, Tim ^a   Schütte, Ute ^c   Höller, Tobias ^a   Riesner, Katarina ^d   Boehm, Diana ^a   Merkelbach Bruse, Sabine ^e   Kirfel, Jutta ^a   Perner, Sven ^a   Gütgemann, Ines ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c Hematology and Oncology ^*  (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Amplification; Fibroblast growth factor receptor 1; Fluorescence in situ hybridization; Pancreatic ductal adenocarcinoma

Indexed keywords

BGJ 398; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TISSUE MICROARRAY; TISSUE SECTION; TUMOR CELL; TUMOR CELL LINE;

EID: 84880750915     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12115     Document Type: Article

References (36)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011; 61; 212-236.
2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the national cancer database. J. Am. Coll. Surg. 1999; 189; 1-7.
3. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15; 2403-2413.
4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 2007; 25; 1960-1966.
5. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 2007; 25; 2212-2217.
6. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 2009; 27; 5513-5518.
7. Kulke MH, Blaszkowsky LS, Ryan DP et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J. Clin. Oncol. 2007; 25; 4787-4792.
8. Conroy T, Desseigne F, Ychou M et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011; 364; 1817-1825.
9. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 2000; 277; 494-498.
10. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010; 10; 116-129.
11. Weiss J, Sos ML, Seidel D et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2010; 2; 62-93.
12. Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 2011; 6; e20351.
13. Goeke F, Franzen A, Menon R et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using FGFR inhibitors. Chest 2012; 142; 1020-1026.
14. Freier K, Schwaenen C, Sticht C et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2007; 43; 60-66.
15. Elbauomy ElsheikhS, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res. 2007; 9; R23.
16. Theillet C, Adelaide J, Louason G et al. FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosom. Cancer 1993; 7; 219-226.
17. Simon R, Richter J, Wagner U et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2001; 61; 4514-4519.
18. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004; 23; 3501-3508.
19. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer 2011; 104; 75-82.
20. Guagnano V, Furet P, Spanka C et al. Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011; 54; 7066-7083.
21. Ney JT, Zhou H, Sipos B et al. Podocalyxin-like protein 1 expression is useful to differentiate pancreatic ductal adenocarcinomas from adenocarcinomas of the biliary and gastrointestinal tracts. Hum. Pathol. 2007; 38; 359-364.
22. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 2003; 442; 444-452.
23. Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed paraffin-embedded tissues. Arch. Pathol. Lab. Med. 2012; 136; 983-992.
24. Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 1993; 53; 4741-4744.
25. Kornmann M, Ishiwata T, Matsuda K et al. IIIC isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells. Gastroenterology 2002; 123; 301-313.
26. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
27. Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010; 70; 2085-2094.
28. Kouhara H, Hadari YR, Spivak-Kroizman T et al. A lipid-anchored GRB2-binding protein that links FGF-receptor activation to the RAS/MAPK signaling pathway. Cell 1997; 89; 693-702.
29. Pellegata NS, Sessa F, Renault B et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994; 54; 1556-1560.
30. Rozenblum E, Schutte M, Goggins M et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997; 57; 1731-1734.
31. Mohammadi M, Honegger AM, Rotin D et al. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (FLG) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol. Cell. Biol. 1991; 11; 5068-5078.
32. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005; 16; 139-149.
33. Guagnano V, Kauffmann A, Wohrle S et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012; 2; 1118-1133.
34. Moore PS, Sipos B, Orlandini S et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of k-ras, p53, p16 and dpc4/smad4. Virchows Arch. 2001; 439; 798-802.
35. Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J. Med. 2010; 77; 606-619.
36. Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am. J. Surg. 2008; 196; 430-441.